<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815867</url>
  </required_header>
  <id_info>
    <org_study_id>PI07-PR-CHOUKROUN</org_study_id>
    <secondary_id>2007/14 CPP</secondary_id>
    <secondary_id>2007-002562-35 EudraCT</secondary_id>
    <nct_id>NCT00815867</nct_id>
  </id_info>
  <brief_title>Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant</brief_title>
  <acronym>Neo-PDGF</acronym>
  <official_title>Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular
      filtration rate estimated 30 days after kidney transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      French study, prospective, multicenter, open, randomized into two parallel groups:

      Group A: NeoRecormon ® 30000 UI: 4 injections Group B: control group without administration
      of the medical product

      Period of recruitment: 18 months Duration of participation of each patient: 90 days Total
      duration of the test: 21 months.

      Main objective : Assessing the effect of epoetin beta on the glomerular filtration rate
      estimated 30 days after kidney transplant.

      Secondary objectives:

      Comparing the 2 groups at all times J0 to J90:

        -  The evolution of renal function

        -  The survival of patients and grafts

        -  The time of onset and incidence of acute rejection proved by biopsy

        -  The correction of anemia

        -  The need for transfusions

        -  The need for EPO

        -  Quality of Life

        -  The safety processing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the effect of epoetin beta on the glomerular filtration rate estimated 30 days after kidney transplant</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The evolution of renal function</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The survival of patients and grafts</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of onset and incidence of acute rejection proved by biopsy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correction of anemia</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for transfusions</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for EPO</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive Epoetin Beta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoetin beta (NeoRecormon ®)</intervention_name>
    <description>comparison of administration of high dosage of epoetin vs no administration of epoetin
30000 UI: 4 injections</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Neorecormon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males anf Females aged between 18 and 75

          -  Patients having given their written consent

          -  Patient determined to participate in the test and to respect the requirements

          -  Patient covered by a social insurance

          -  Patient to be kidney transplanted (from a cadaveric donor)

          -  Patient benefiting from the 1st or 2nd kidney transplant

          -  Patient formerly treated by peritoneal dialysis or hemodialysis

          -  Patient receiving a graft with risk of delayed graft function (score&gt; 7 combining age
             of the donor, ischemia time, receiver ethnicity and cause of death)

          -  Patient to receive treatment with basiliximab, mycophenolate mofetil, tacrolimus and
             corticosteroid

        Exclusion Criteria:

          -  Patient Pregnant or nursing

          -  Patient with a disability that does not ensure the good understanding of the study and
             its imperatives , or patient having dependency (alcohol, drugs)

          -  Patient receiving doses of epoetin beta or alpha&gt; 30,000 IU / week or darbepoetin&gt; 150
             microg / week before transplanting

          -  Patient who has participated in a clinical trial in the last month or currently
             included in another test

          -  Patient in safeguarding justice, guardianship or trusteeship

          -  Patient receiving a third transplant or hyper immune or who have a positive historic
             cross-match

          -  Patient receiving a preemptive transplant

          -  graft from a living donor

          -  graft with 3 or more arteries

          -  Multi-Organ Transplantation

          -  Patient with heart failure stage&gt; III

          -  Patients with unstable ischemic heart disease, or have had a major coronary event less
             than 6 months, stroke or TIA &lt;6 months or symptomatic arteritis of lower limbs stage ≥
             3

          -  Patients with active viral infection: hepatitis B, C (PCR + only) or HIV

          -  Patient with a history of anemia from erythroblastopenia

          -  Patient receiving anticoagulant treatment(AVK) before renal transplantation and to be
             continued after transplant

          -  Patient with a preoperative rate Hb&gt; 14 g / dL (before ultrafiltration)

          -  A patient with known hypersensitivity to the active substance or to any of the
             excipients, or to benzoic acid

          -  Patients with poorly controlled hypertension in the weeks before transplantation
             (Diastolic Blood Pressure ≥ 110 mm Hg with more than 3 antihypertensive drugs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHOUKROUN Gabriel, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARTINEZ Franck, Ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necker Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amiens hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA CAVALE BLANCHE Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MONDOR Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MICHALLON Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kremlin Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALBERT CALMETTE Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes, Hotel-Dieu Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice, Pasteur Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georges Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TENON Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA MILETRIE Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAISON BLANCHE Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bois Guillaume Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FOCH Hospital</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RANGUEIL Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRETONNEAU Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2008</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney failure</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>graft function</keyword>
  <keyword>haemoglobin</keyword>
  <keyword>epoetin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

